Colac

Quick links to important sections

Colac

Method of action: Laxative

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colac

What is Colac?

Colac is a medicinal product classified as a stimulant laxative. It is primarily used to address occasional constipation by facilitating bowel movements. The active component in Colac is bisacodyl, a diphenylmethane derivative that has been used in clinical practice for several decades.

Mechanism of Action

Colac works by acting directly on the lining of the colon. When bisacodyl reaches the large intestine, it stimulates the nerve endings in the intestinal wall. This stimulation increases peristalsis, which are the rhythmic muscle contractions that move stool through the digestive tract.

Additionally, the medication alters the water and electrolyte secretion in the bowels. By increasing the accumulation of fluids within the intestinal lumen, it helps to soften the stool, making it easier to pass.

General Characteristics

  • Type of Relief: It is designed for short-term use to provide relief from acute constipation.
  • Formulation: Colac is typically available in oral tablet form, often featuring an enteric coating. This coating is designed to prevent the active ingredient from being released in the stomach or small intestine, ensuring it reaches the colon where it is most effective.
  • Onset of Action: When taken orally, the effects generally manifest within 6 to 12 hours, which is why it is often associated with overnight relief.

What side effects are possible with Colac?

Possible Side Effects and Safety Information

The safety profile for Colac (Bisacodyl), a stimulant laxative, is primarily structured around adverse reactions affecting the Gastrointestinal System. The most frequent effects are documented in official regulatory documents based on incidence observed in clinical use.


Official Adverse Reaction Categories

Classification Examples of Reactions
Common Abdominal pain, abdominal discomfort, diarrhea
Uncommon Nausea, vomiting, abdominal distension, dizziness, dehydration
Rare Hypersensitivity reactions, syncope (fainting)
Not Known Anaphylactic reactions, colitis (including ischaemic colitis), proctitis

Safety Considerations and Constraints

The most frequent adverse events, such as abdominal discomfort and diarrhea, may be more prominent at the start of treatment. Serious adverse reactions documented in post-marketing reports include severe fluid and electrolyte loss, which is associated with prolonged or excessive use, and rare occurrences of anaphylactic reactions.

Regulatory safety information explicitly notes constraints related to the duration of use. The medication is not intended for daily, continuous use, as chronic exposure is associated with the potential for laxative dependence and serious electrolyte imbalance or colonic atony.

Specific safety considerations are noted for certain groups. For children, administration requires professional medical consultation. Older adults may have an increased risk of dehydration and electrolyte disturbances.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Colac (Bisacodyl) overdose is focused on the manifestations of excessive pharmacological effect and the resulting severe physiological consequences.

Documented Overdose Manifestations

Acute overdose is characterized by symptoms of extreme hyper-peristalsis, including diarrhea, severe abdominal cramping, and vomiting. These manifestations are documented to lead to clinically significant fluid and electrolyte loss. The primary serious outcomes stem from this derangement, specifically severe dehydration, hypokalemia (low potassium), and metabolic alkalosis, which may require intensive clinical intervention. There is no known specific antidote for Bisacodyl overdose; treatment is strictly supportive and symptomatic.

Emergency Actions and Required Medical Help

Regulatory authorities mandate that any suspected overdose requires immediate medical attention. You must get medical help or contact a Poison Control Center right away. Immediate hospitalization may be necessary for cases involving severe symptoms, such as collapse or signs of profound electrolyte imbalance.

Overdose management requires professional monitoring, including measurement of vital signs and laboratory testing of electrolytes. This correction of fluid and electrolyte imbalances is noted to be especially critical in vulnerable populations, as dehydration is more common in children and the elderly following a laxative overdose.

Therapeutic Uses of Colac

What Colac Treats: Main Uses and Benefits

Colac is applied in conditions characterized by periods of heightened symptoms related to acute, non-daily constipation, and may be part of symptomatic management. Bisacodyl is used for managing symptoms of constipation and is relevant in clinical settings for pre-procedure symptomatic support.


Easing Episodic and Difficult Constipation

Colac is used in situations involving certain distressing symptoms related to infrequent or difficult bowel movements, and is applied when short-term symptomatic assistance is needed. The medication is commonly used to help with symptoms of occasional constipation, the physical discomfort of hard stools, and the need for straining. It offers symptomatic relief that may assist patients with maintaining a sense of stability when symptoms are more noticeable.

Applied in clinical settings where supportive symptom management is appropriate for acute, temporary changes in bowel function.

Managing Physical Symptoms and Clinical Scenarios

The product is relevant for easing symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load. It is also applied in clinical settings that involve acute or unstable symptom patterns, relevant in contexts involving pre-procedure symptomatic support before certain diagnostic procedures or surgery, and managing constipation linked to opioid pain medication. This support may assist with maintaining a sense of stability and comfort during symptomatic periods.


Quick Fact: Relief for Acute Constipation

Colac is primarily used to address symptoms related to acute or episodic changes, helping to ease the physical discomfort and difficulty associated with hard, infrequent stools.

Eligibility and Restrictions for Use

Who Can and Cannot Use Colac? Official Eligibility

Regulatory agencies define specific population rules for the use of Colac (Bisacodyl), focusing on absolute prohibitions and conditional use.


Absolute Contraindications

Colac must not be used by patients diagnosed with specific acute or severe conditions, including gastrointestinal obstruction or ileus, acute abdominal conditions (such as appendicitis or acute inflammatory bowel disease), or severe dehydration [Source 1.3, 3.1]. Use is also prohibited for individuals with a known hypersensitivity to Bisacodyl or any of its inactive ingredients [Source 1.3, 3.5].

Age and Physiological Restrictions

  • Adults are generally eligible for use. For children under 12 years of age, use is often conditional and requires the guidance of a physician or pharmacist [Source 1.2, 3.2]. Tablets are not recommended for children under six years [Source 3.5].
  • Pregnancy and Lactation: Use during pregnancy is generally not recommended, especially in the first trimester, unless deemed necessary by a physician [Source 2.1]. Use during breastfeeding is usually considered acceptable [Source 2.2].
  • Conditional Use: Patients with certain pre-existing conditions, such as the elderly or those with risk of renal insufficiency, must discontinue use and only restart under medical supervision if harmful fluid loss occurs [Source 1.3, 3.4]. Rectal forms are contraindicated in the presence of anal fissures or ulcerative proctitis [Source 3.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes formally documented drug-drug and drug-food interaction patterns for the active ingredient Bisacodyl, strictly based on official government regulatory documents.


Administration Timing Interactions (Premature Dissolution Risk)

Bisacodyl is formulated as an enteric-coated tablet, and regulatory labeling mandates specific timing rules to maintain the coating's integrity. The co-administration of antacids, milk products, or Proton Pump Inhibitors (PPIs) is documented to cause the premature dissolution of the enteric coating. Administration of Bisacodyl tablets must be separated from antacids and milk products by at least one hour to prevent this interaction.


Systemic Pharmacodynamic Interactions (Electrolyte Risk)

Regulatory information notes that co-administration of Bisacodyl with diuretics or adrenocorticosteroids (corticosteroids) may enhance the potential for potassium loss (hypokalaemia). This pharmacodynamic effect creates a secondary restriction risk: concurrent use with medicines that prolong the QT interval is restricted, as the risk of cardiac arrhythmia is increased if this electrolyte imbalance occurs. Other laxative products, when used concurrently, may increase the incidence of gastrointestinal side effects.

Mechanism of Action

The active ingredient, Bisacodyl, is inactive until converted to its metabolite, BHPM, a process that occurs exclusively in the large intestine. BHPM then produces a dual mechanism that acts locally on the colon.


Direct Prokinetic Stimulation of Colonic Motility

The active metabolite directly engages the Enteric Nervous System (ENS) neurons and the mucosa, functioning as a stimulant. This action initiates and enhances parasympathetic reflexes and High-Amplitude Propagated Contractions (HAPCs) in the smooth muscle wall. This mechanistic domain causes an acceleration of the transit time of contents through the large intestine.


Active Modulation of Epithelial Fluid Transport

BHPM modulates the transport properties of the colonic epithelial cells by influencing key signaling pathways, including the local release of Prostaglandin E2 and the downregulation of water channels like Aquaporin-3 (AQP3). This mechanism shifts the epithelial process from net reabsorption to net secretion of water and electrolytes into the lumen, causing an increase in the intraluminal fluid volume and modulating the consistency of the colonic contents.

Dosage and Administration Information

This section outlines the administration and usage parameters for Colac (Bisacodyl).

Administration Scope

Scope Instruction
Route of Administration Oral (delayed-release tablets) or Rectal (suppositories).
Dosing Schedule Adults and children 12 years and older: 5 mg to 15 mg (1 to 3 tablets) once daily. Children 6 to under 12 years: 5 mg (1 tablet) once daily. Rectal administration is typically 10 mg for adults and older children.
Frequency Once daily. Oral tablets are often taken at bedtime to produce an effect in 6 to 12 hours.

Procedural Rules and Constraints

The drug is intended for short-term use only and should not be used for more than one week unless directed by a healthcare professional.

Oral Administration Constraints:

  • Do not chew or crush the enteric-coated tablet. It must be swallowed whole with water.
  • Do not take the tablet within one hour of consuming an antacid or milk. This restriction prevents the premature dissolution of the tablet's protective coating in the stomach.

Age-Specific Use:

  • Oral administration is not recommended for children under 6 years old due to the requirement to swallow the tablets whole.

Following these administration rules ensures the medication is taken as intended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colac (Bisacodyl)


Evidence for Use in Acute and Episodic Constipation

Research exploring the effects of Bisacodyl, the active ingredient in Colac, has included short-term randomized controlled trials (RCTs). Studies were generally designed as placebo-controlled trials, where patient outcomes were monitored alongside those receiving an inactive compound. The research primarily focused on acute or episodic symptom patterns related to occasional constipation and the monitoring of specific functional outcomes.

The main focus of these studies was studied for measuring the time elapsed until the first successful bowel movement occurred. Trials also monitored how symptoms evolved in the observed populations, with studies reporting measurements related to stool consistency using standard functional measures. Data are still emerging for long-term or repeated use in this episodic context, and results apply only to the populations studied under these specific, controlled conditions.


Evidence for Use in Chronic Functional Constipation

Bisacodyl was evaluated in systematic reviews and meta-analyses that consolidated data from multiple randomized trials of individuals with chronic functional constipation. These studies explored how symptoms change over time and assessed outcomes reflecting daily functioning, such as measuring the weekly number of Complete Spontaneous Bowel Movements (CSBMs) and patient-reported Quality of Life (QoL) metrics.

A key research limitation is that the majority of individual RCTs included in these reviews have follow-up durations that were limited to short or intermediate periods, such as four weeks. High-quality, long-term randomized data characterizing outcomes over extended periods for six months or longer are less prevalent, meaning outcomes related to long-term effects are not fully established.


Research on Bowel Preparation for Medical Procedures

Research in this area primarily involves meta-analyses of RCTs and head-to-head trials comparing different preparatory regimens used before diagnostic procedures. In this research context, Bisacodyl was studied for use as one component within a multi-drug protocol, often combined with osmotic laxatives. The primary outcomes monitored were the quality of bowel cleansing (assessed via standardized scoring systems) and the successful completion rate of the procedure.

The evidence focuses heavily on the efficacy of the entire combination regimen, making it challenging to precisely differentiate the contribution of Bisacodyl as a single agent within the protocol. Comparative evidence is lacking for Bisacodyl as a standalone agent for this indication, as it is typically used as an adjunct to a main osmotic agent.

Key Studies & References Low-volume polyethylene glycol and bisacodyl for bowel preparation prior to colonoscopy: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Colac (FAQ)

Q: Is it okay to take Colac if I occasionally drink alcohol?

A: Official information does not indicate a specific interaction between Bisacodyl (the active ingredient in Colac) and alcohol. Regulatory information indicates that concurrent use of Bisacodyl and alcohol is not specifically restricted. Concerns about alcohol and Bisacodyl use can be discussed with a healthcare provider.


Q: Are there any long-term effects associated with using Colac?

A: Official regulatory documents emphasize that Colac is intended only for short-term use. Taking this medicine daily or for a prolonged period (more than one week) is associated with serious risks, including laxative dependence and the potential for severe electrolyte imbalance and loss of normal bowel function. The importance of adhering to the label directions is noted for safety.


Q: How long does Colac usually stay in your system after stopping treatment?

A: The active substance of Colac is converted into an active metabolite (BHPM) in the colon. The active substance is eliminated from the body within a relatively short period, and its half-life has been reported to be approximately 7 to 10 hours.


Q: Can Colac interfere with birth control pills?

A: Colac is not specifically documented to interact directly with birth control pills. However, if Colac causes severe or prolonged diarrhea (lasting more than 24 hours), this may potentially reduce the effectiveness of oral contraceptives. Patients who experience severe or prolonged diarrhea while taking Bisacodyl and use oral contraceptives should discuss this with their healthcare provider.


Q: What are some signs that Colac is starting to work for me?

A: The primary indicator that Colac is working is the occurrence of a bowel movement. Official product information notes that the oral tablet typically works to produce a bowel movement within a timeframe of 6 to 12 hours following administration. This timing is the main measure of its effectiveness.


Q: Can taking Colac affect the results of lab tests (blood work, etc.)?

A: Short-term use is generally not associated with changes in lab test results. However, prolonged or excessive use of Bisacodyl is warned against because it can lead to a loss of essential minerals, specifically potassium (hypokalaemia). This electrolyte imbalance can impact the results of blood tests.


Q: Is it normal to feel a mild headache when first starting Colac?

A: Headache is not explicitly listed as a common or uncommon side effect in some major regulatory labels. Dizziness, which is a potential side effect, is noted in the uncommon category. Persistent or severe headaches can be discussed with a healthcare provider.


Q: Is Colac a prescription-only medication?

A: Colac (Bisacodyl) is widely classified as an Over-the-Counter (OTC) Drug Product by regulatory agencies. This indicates that it is available for purchase without a prescription. It is important to adhere closely to the directions and warnings provided on the product label.


Q: Is there a risk of dependency or addiction with Colac?

A: Official warnings state that frequent or continued use beyond the recommended period can lead to laxative dependence, where the bowels may lose their normal function. This is a risk associated with the prolonged use of stimulant laxatives.


Q: What should I do if a side effect from Colac seems concerning?

A: The official label advises that use of the product should be discontinued, and medical attention should be sought, if certain concerning symptoms arise. These include rectal bleeding, failure to have a bowel movement after use, or signs of a serious allergic reaction, such as swelling or difficulty breathing.


Q: Is it possible to develop a tolerance to Colac?

A: Regulatory warnings against long-term use highlight the potential for the body to become reliant on the product, which is often described as laxative dependence. This reliance means the colon may require the medicine to function, which can be linked to the development of tolerance over time.


Q: What are the signs of a rare but serious reaction to Colac?

A: Serious reactions are rare, but product monographs document signs like fainting (syncope) and severe fluid and electrolyte loss. Anaphylactic reactions are also noted, which includes symptoms that necessitate professional medical evaluation.


Q: Can using Colac cause temporary changes in appetite?

A: While Colac is not directly listed as affecting appetite, common side effects include abdominal discomfort, nausea, and vomiting. Experiencing these gastrointestinal symptoms may be associated with temporary changes in appetite during the period of use.


Q: Can Colac be taken on an empty stomach?

A: The official product directions require taking the oral tablets with water. The primary focus of the restriction is to avoid milk and antacids within one hour. This suggests the timing relative to other food intake is generally flexible, provided the tablet is taken with water as instructed.


Q: Are there any specific dietary guidelines recommended while taking Colac?

A: The most critical dietary guideline specified in the drug label is to avoid milk products within one hour of taking the enteric-coated tablet. This restriction is necessary to ensure the integrity of the enteric coating and proper function of the medicine.

How should Colac be stored and disposed of?

How to Store and Dispose of Colac?

Storage of Colac (Bisacodyl) must strictly follow official regulatory guidelines to maintain its stability and ensure child safety.

Mandatory Storage Conditions

Requirement Details (Regulatory Standard)
Temperature Store at controlled room temperature, typically 20 C to 25 C. Do not freeze.
Container Keep in the original container, and ensure it is tightly closed.
Protection Protect the product from moisture, excessive heat, and light. Do not store in the bathroom.
Child Safety Store strictly out of the reach and sight of children.

Disposal Instructions

Unused or expired Colac must be disposed of according to official regulatory guidelines. The preferred method is using a designated drug take-back program or authorized collection site. The medicine must not be flushed down a toilet or poured into a drain unless explicitly permitted by the product labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Colac found in:

A-Z Index: